AstraZeneca grows oncology portfolio with Pinetree’s EGFR degrader
AstraZeneca will pay $45m upfront and up to $500m in milestone-based payments for licensing Pinetree’s pre-clinical EGFR degrader.
25 July 2024
25 July 2024
AstraZeneca will pay $45m upfront and up to $500m in milestone-based payments for licensing Pinetree’s pre-clinical EGFR degrader.
The crowd and panel gave Gilead a standing ovation after the full data from the Phase III PURPOSE trial was announced at AIDS 2024.
Dren Bio is eligible to receive $2.85bn in preclinical, clinical, regulatory and commercial milestone payments.
The approval encompasses four variations of the Comirnaty JN.1 vaccine, following the International Recognition Procedure.
The Phase II antibody drug conjugate received FDA fast track designation against treatment-resistant head and neck carcinoma.
Trials have shown that tenecteplase is effective in dissolving blood clots and averting the formation of new ones.
The study found that the risk of certain side effects peak by two weeks for lymphoma patients receiving three CAR-T therapies.
Telix’s ‘cold kit’ will “improve equity of access” to PSMA-PET imaging, the company’s CEO says.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.